 This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB TCRζ4-1BB co-stimulatory domains referred to as CART22 cells in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. 